| 1 |
35440080 | Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression. | 2022 Apr 19 |
1 |
| 2 |
33671112 | An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3β/β-Catenin/STAT3/CD44 Suppressor with Anti-Glioblastoma Properties. | 2021 Feb 28 |
1 |
| 3 |
34166727 | Lithocholic acid-tryptophan conjugate (UniPR126) based mixed micelle as a nano carrier for specific delivery of niclosamide to prostate cancer via EphA2 receptor. | 2021 Aug 10 |
1 |
| 4 |
30551901 | Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype. | 2019 Jan 15 |
5 |
| 5 |
30611787 | Niclosamide alleviates pulmonary fibrosis in vitro and in vivo by attenuation of epithelial-to-mesenchymal transition, matrix proteins & Wnt/β-catenin signaling: A drug repurposing study. | 2019 Mar 1 |
2 |
| 6 |
30635359 | Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy. | 2019 Feb 8 |
7 |
| 7 |
30842311 | New insights into niclosamide action: autophagy activation in colorectal cancer. | 2019 Mar 6 |
2 |
| 8 |
31208945 | Stress Conditions Induced by Locoregional Therapies Stimulate Enrichment and Proliferation of Liver Cancer Stem Cells. | 2019 Dec |
1 |
| 9 |
28389414 | Niclosamide: Beyond an antihelminthic drug. | 2018 Jan |
1 |
| 10 |
29528187 | Down-regulation of dishevelled-2 inhibits cell proliferation and invasion in hepatoblastoma. | 2018 Jul |
1 |
| 11 |
29544454 | Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial. | 2018 Mar 15 |
1 |
| 12 |
29603892 | Niclosamide, a Drug with Many (Re)purposes. | 2018 Jun 6 |
1 |
| 13 |
29721216 | Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. | 2018 Apr 10 |
1 |
| 14 |
29783777 | Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer. | 2018 May 20 |
1 |
| 15 |
30053001 | Feminizing Adrenocortical Carcinoma: The Source of Estrogen Production and the Role of Adrenal-Gonadal Dedifferentiation. | 2018 Oct 1 |
1 |
| 16 |
30143678 | The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC. | 2018 Aug 24 |
4 |
| 17 |
30274939 | Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth. | 2018 Nov 1 |
2 |
| 18 |
28233680 | Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis. | 2017 Mar 15 |
4 |
| 19 |
28529629 | The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo. | 2017 |
7 |
| 20 |
28828438 | Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth. | 2017 Aug 31 |
2 |
| 21 |
28861168 | Inhibition of Wnt/β-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma. | 2017 |
8 |
| 22 |
28877265 | Niclosamide induces protein ubiquitination and inhibits multiple pro-survival signaling pathways in the human glioblastoma U-87 MG cell line. | 2017 |
1 |
| 23 |
27338550 | The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway. | 2016 Jun 1 |
1 |
| 24 |
27363012 | Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling. | 2016 Jul 5 |
6 |
| 25 |
27888804 | Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. | 2016 Dec 27 |
1 |
| 26 |
25174399 | WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. | 2015 Jun |
3 |
| 27 |
26186072 | Niclosamide Analogs for Treatment of Ovarian Cancer. | 2015 Oct |
1 |
| 28 |
26272032 | Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure. | 2015 Sep 1 |
3 |
| 29 |
26716739 | [Molecular mechanisms of niclosamide antitumor activity]. | 2015 Nov-Dec |
1 |
| 30 |
24552774 | Effect of niclosamide on basal-like breast cancers. | 2014 Apr |
4 |
| 31 |
24732808 | Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. | 2014 Jul 10 |
1 |
| 32 |
24736023 | Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. | 2014 Jul |
3 |
| 33 |
23453073 | Small molecule modulators of Wnt/β-catenin signaling. | 2013 Apr 1 |
2 |
| 34 |
23908450 | Anticancer effects of niclosamide in human glioblastoma. | 2013 Aug 1 |
1 |
| 35 |
22237038 | Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. | 2012 Apr |
1 |
| 36 |
21531761 | Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. | 2011 Jun 15 |
4 |
| 37 |
22195040 | Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway. | 2011 |
5 |
| 38 |
19772353 | The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. | 2009 Nov 3 |
1 |